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Simple Summary: Currently, there is a need for prognostic tools that can stratify patients, who present
with primary disease, based on whether they are at low or high risk for drug resistant and
hormone-independent lethal metastatic prostate cancer. The aim of our study was to assess the
potentially added value of tumor microenvironment (stroma) components for the characterisation of
prostate cancer. By utilising patient derived-xenograft models we show that the molecular properties of
the stroma cells are highly responsive to androgen hormone levels, and considerable ECM remodelling
processes take place not only in androgen-dependent but also in androgen-independent tumor models.
Transcriptomic mechanisms linked to osteotropism are conserved in bone metastatic xenografts,
even when implanted in a different microenvironment. A stroma-specific gene list signature was
identified, which highly correlates with Gleason score, metastasis progression and progression-free
survival, and thus could potentially complement current patient stratification methods.
Abstract: Resistance acquisition to androgen deprivation treatment and metastasis progression are
a major clinical issue associated with prostate cancer (PCa). The role of stroma during disease
progression is insufficiently defined. Using transcriptomic and proteomic analyses on differentially
aggressive patient-derived xenografts (PDXs), we investigated whether PCa tumors predispose their
microenvironment (stroma) to a metastatic gene expression pattern. RNA sequencing was performed
on the PCa PDXs BM18 (castration-sensitive) and LAPC9 (castration-resistant), representing different
disease stages. Using organism-specific reference databases, the human-specific transcriptome (tumor)
was identified and separated from the mouse-specific transcriptome (stroma). To identify proteomic
changes in the tumor (human) versus the stroma (mouse), we performed human/mouse cell separation
and subjected protein lysates to quantitative Tandem Mass Tag labeling and mass spectrometry.
Tenascin C (TNC) was among the most abundant stromal genes, modulated by androgen levels
in vivo and highly expressed in castration-resistant LAPC9 PDX. The tissue microarray of primary
PCa samples (n = 210) showed that TNC is a negative prognostic marker of the clinical progression to
recurrence or metastasis. Stroma markers of osteoblastic PCa bone metastases seven-up signature
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were induced in the stroma by the host organism in metastatic xenografts, indicating conserved
mechanisms of tumor cells to induce a stromal premetastatic signature. A 50-gene list stroma signature
was identified based on androgen-dependent responses, which shows a linear association with the
Gleason score, metastasis progression and progression-free survival. Our data show that metastatic
PCa PDXs, which differ in androgen sensitivity, trigger differential stroma responses, which show the
metastasis risk stratification and prognostic biomarker potential.
Keywords: prostate cancer; stroma signature; patient-derived xenografts
1. Introduction
Bone metastases are detected in 10% of patients already at the initial diagnosis of prostate cancer
(PCa) or will develop in 20–30% of the patients subjected to radical prostatectomy and androgen
deprivation therapy and will progress to an advanced disease called castration-resistant prostate
cancer [1]. Metastases are established when disseminated cancer cells colonize a secondary organ
site. An important component of tumor growth is the supportive stroma: the extracellular matrix
(ECM) and the nontumoral cells of the matrix microenvironment (e.g., endothelial cells, smooth muscle
cells and cancer-associated fibroblasts). Upon interaction of the stroma compartment and tumor cells,
the stroma responds by the secretion of growth factors, proteases and chemokines, thereby facilitating
the remodeling of the ECM and, thus, tumor cell migration and invasion [2]. Therefore, tumor cell
establishment requires an abnormal microenvironment. It is unclear whether the stroma is modulated
by the tumor cells or by intrinsic gene expression alterations. Understanding the mechanisms of tumor
progression to the metastatic stage is necessary for the design of therapeutic and prognostic schemes.
The bone microenvironment is favorable for the growth of PCa, as well as breast cancer, indicated
by the high frequency of bone metastasis in these tumors. Studies have shown that cancer cell growth
competes for the hematopoietic niche in the bone marrow with the normal residing stem cells [3],
and depending on the cancer cell phenotype, this may lead to either osteoblastic or osteolytic lesions.
The stroma signature of osteolytic PCa cells (PC-3) xenografted intraosseously in immunocompromised
mice induce a vascular/axon guidance signature [4]. The stroma signature of osteoblastic lesions from
human VCap and C4-2B PCa cell lines indicated an enrichment of the hematopoietic and prostate
epithelial stem cell niche. A curated prostate-specific bone metastasis signature (Ob-BMST) implicated
seven highly upregulated genes (Aspn, Pdgrfb, Postn, Sparcl1, Mcam, Fscn1 and Pmepa1) [5], among which,
Postn and Fscn1 are bone-specific. Furthermore, Aspn and Postn expression is also increased in primary
PCa cases [5], indicative of osteomimicry processes. The induction of osteoblastic genes in the stroma
of primary tumors (PCa and breast), such as osteopontin and osteocalcin, has been suggested as a
mechanism termed osteomimicry [6] to explain why the bone microenvironment is the preferential
metastasis site. High stromal differences between benign, indolent and lethal PCa, combined with the
enrichment of bone remodeling genes in high Gleason score cases [7], suggest that the stroma is an
active player in PCa. During androgen deprivation, androgen-dependent epithelial cells will undergo
apoptosis, while the supporting stroma is largely maintained or replaces the necrotic tissue areas [8].
Stromal cells do express androgen receptors (AR) and have active downstream signaling, while the
absence of stromal AR expression is used as a prognostic factor of disease progression [9]. Furthermore,
AR binds to different genomic sites in prostate fibroblasts compared to the epithelium [10] and to
cancer-associated fibroblasts (CAFs) [11], indicating different roles of AR in epithelial or stroma cellular
contexts. Prostate CAFs have tumor-promoting effects on marginally tumorigenic cells (LNCaP),
irreversibly altering their phenotype and influencing their progression to androgen independence and
metastasis [12,13].
In this study, we investigated whether metastatic PCa patient-derived xenograft models (PDXs)
that differ in androgen sensitivity are triggering a differential stroma response. To elucidate the
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mechanisms of stroma contribution to tumor growth later on, we determined the unique gene
expression profile of the stroma compared to the tumor compartment, the proteome changes of the
tumor versus stroma. We identified androgen-dependent stroma gene expression signatures with
potential disease progression prognostic values for primary PCa.
2. Results
2.1. Simultaneous Transcriptome Analysis of Human and Murine Signatures in PDXs Can Distinguish
Androgen-Dependent Expression Changes in Tumor and Host-Derived Stroma
We analyzed the transcriptome of bulk PDX tumors grown subcutaneously in immunocompromised
murine hosts by next-generation RNA-sequencing (RNA-Seq). Bone metastasis (BM)18 and LAPC9
PDXs were used in three different states: intact, post-castration (day 8 LAPCa9 and day 14 BM18) and
androgen replacement (24 h) (Figure 1A). Tumor growth kinetics revealed the androgen-dependent
phenotype of BM18, which regressed completely in two weeks post-castration (Figure 1B), and the
androgen-independent phenotype of LAPC9 PDX tumors, which grew exponentially even after
castration (Figure 1C), thus confirming the differential aggressiveness of the two models. The reduction
of epithelial glands and proliferating Ki67+ cells in the BM18 castrated conditions (Figure 1D) was in
contrast to the LAPC9 tumors (Figure 1E), which were morphologically indistinguishable among intact
and castrated hosts. Bulk tumor tissues, which contain human tumor cells and mouse infiltrating
stroma cells, were simultaneously analyzed from the same samples by RNA-Seq. To distinguish the
transcriptome of the different organisms, the mouse and human reads were separated by alignment
to a mouse and a human reference genome, respectively. Principal component analysis (PCA) of the
human (tumor) 500 most variable genes showed that both castrated and replaced groups have altered
expression profiles among each other and compared to the intact tumors. This was the case for the BM18
(Figure 2A) and the LAPC9 human transcriptomes (Figure 2B). The response to short-term androgen
replacement showed a larger degree of variability in the BM18 (Figure 2A). However, the expression
levels of direct AR target genes (KLK3, NKX3.1 and FKBP5) identified by the RNA-Seq confirmed
that androgen levels affected the activation of androgen receptor signaling in both BM18 (Figure 2C)
and LAPC9 (Figure 2D, KLK3 and NKX3.1). Differential expression analysis of the most variable
human (tumor) genes, showed high variability among the castrated and intact groups, for both BM18
(Figure S1A) and LAPC9 (Figure S1B) transcript levels, while the LAPC9 replaced and castrated groups
had similar profile among each other, discriminating them from the intact condition (Figure S1B).
PCA analysis of the BM18 mouse (stroma) transcriptome indicated that the majority of castrated
samples (with and without 24-h androgen replacement) diverged from the intact tumor (Figure 2E).
The LAPC9 mouse (stroma) transcriptome instead did not show specific clustering within or between
the sample groups when plotting the top 500 most variably expressed genes (Figure 2F). The Ob-BMST
signature of all seven genes (Aspn, Pdgrfb, Postn, Aspn, Sparcl1, Mcam, Fscn1 and Pmepa1), which were
upregulated in the bone stroma, as previously identified [5], were indeed expressed in the primary
PCa TCGA cohort, as well as in both BM18 and LAPC9 PDXs (Figure S2A). Pdgrfb, Postn, Aspn and
Sparcl1, specifically in the mouse RNA-Seq data, thus, are stroma-specific. Collectively, the Ob-BMST
gene signature is expressed at equal levels in the BM18 and LAPC9 (intact) (Figure S2A). Some of these
genes were differentially expressed upon castration in the BM18 (Figure 2G) but not in the LAPC9
(Figure 2H). A bone microenvironment-specific stroma signature induced by osteoblastic cell lines was
conserved in bone metastasis PDXs maintained in other microenvironments and found in primary
prostatic tissues.
Cancers 2020, 12, 3786 4 of 29
Figure 1. In vivo tumor growth properties of androgen-dependent BM18 versus androgen-independent
patient-derived xenograft (PDX) models. (A) Scheme of in vivo BM18 and LAPC9 experiments,
including the timeline of castration, androgen replacement (single dihydrotestosterone (DHT)
administration) and collection of material for transcriptomic analysis. (B) BM18 PDX tumor growth
progression in time. Groups: (1) intact tumors (collected at max size, n = 3), (2) castrated (day 14,
n = 4) and (3) castrated, followed by testosterone readministration (castrated-testosterone) (day 15
since castration and 24 h since the androgen receptor (AR), n = 3). R; right tumor, L; left tumor per
animal. (C) LAPC9 PDX tumor growth progression in time. Groups: (1) intact tumors (collected at max
size, n = 3), (2) castrated (day 8, n = 4) and (3) castrated, followed by testosterone readministration
(castrated-testosterone) (day 9 since castration and 24 h since AR, n = 3). Tumor scoring was performed
weekly by routine palpation; values represent average calculations of the tumors of all animals per
group (considering 2 tumors, left, L, and right, R, of each animal). Error bars represent SEM, calculated
considering the no. of animals for each time point. Ordinary two-way ANOVA with Tukey’s multiple
comparison correction was performed, p < 0.01 (**) and p < 0.0001 (****). (D) Histological morphology of
BM18 and (E) LAPC9 (from intact, castrated and androgen-replaced hosts), as assessed by Hematoxylin
and Eosin staining (H&E, top). Scale bars: 20 µm, and proliferation marker Ki67 protein expression
(bottom panel).
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Figure 2. Separation of human (tumor) and mouse (stroma) transcriptomes of BM18 and LAPC9
tumors. (A,B) Principal component analysis plot of the gene expression of the 500 most variable
genes on all samples; BM18 human transcripts (A) and LAPC9 human (B) at intact, castrated and
replaced (castrated + 24 h AR) conditions. (C,D) Expression values of AR direct target genes as
detected by RNA-Seq (transcript per million (TPM) counts) in the BM18 (C) or LAPC9 (D) tumors
as confirmation of the effective repression of AR downstream signaling by castration. Intact (n = 3),
castrated (n = 4) and replaced (n = 3). (E,F) Principal component analysis plot of the gene expression of
the 500 most variable genes on all samples, BM18 mouse (E) and LAPC9 mouse (F) at intact, castrated
and replaced (castrated + 24 h AR) conditions. (G,H) Expression values of the prostate-specific bone
metastasis signature (Ob-BMST) seven upregulated stroma signature genes, as detected by RNA-Seq
(TPM normalized counts) in the mouse transcriptome of BM18 (E) or LAPC9 (F) tumors.
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2.2. Proteomic Analysis Provides Functional Information over the Identified Human/Mouse-Specific Transcriptome
To study the proteome of the tumor versus the stroma, human and mouse cell fractions were
isolated by the magnetic cell sorting (MACS) mouse depletion method from tumor sample preparations:
BM18 and LAPC9 each at the intact, castrated and replaced states. Protein lysates of either mouse
or human origins (single replicate from a pool of n = 3 to 4 biological replicates per condition) were
subjected to an in-solution tryptic digest following Tandem Mass Tag (TMT)-labeling of the resulting
peptides and their mass spectrometric analysis (Figure 3A).
In addition to the initial experimental separation of the protein lysates, we further explored the
species homologs of the identified proteins by computational analysis using a combined human and
mouse protein sequence database. We identified 4198 proteins in the sample that were enriched for
human cells. Thereof, 3154 were human-specific proteins, with 996 revealing a high homology shared
among human and mouse, and only a fraction of 48 mouse-specific, peptides. (Figure 3B, left plot).
For samples enriched in mouse cells, we identified, in total, 5192 proteins; thereof, 2486 mouse-specific
proteins, 2379 shared homologs and 247 human-specific (Figure 3B, right plot). We searched for
prostate specific markers such as KLK3, a prostate-specific antigen that is secreted by luminal cells.
In the proteomic data, the human-specificity was confirmed, and the secreted protein was found also
in the mouse fraction (Figure 3C). To further ensure that the proteomic data were indeed identifying
real stromal-specific candidates, we searched specifically for the seven-gene Ob-BMST signature found
also to be expressed in both BM18 and LAPC9. POSTN, PDGFRB and MCAM (Figure 3C) were indeed
detected at the protein level, thus might have a functional role, and were found exclusively in the
mouse fraction (Figure 3C, right plot) and hybridizing with mouse-specific sequences (Figure 3C,
triangle indicates Mus Musculus species specificity).
2.3. Differential Expression Analysis Reveals Androgen-Dependent Stromal Gene Modulation in
Androgen-Independent PDX Model
The relative ratio of human and mouse transcript reads reflected a higher stroma content in the
BM18 compared to LAPC9 and significantly reduced human tumor content with enriched stroma
content in the BM18 castrated group (Figure S2B). No major differences were observed in the LAPC9
castrated group (Figure S2C). We demonstrated that the human (tumor), as well as the mouse (stroma),
transcriptomes follow androgen-dependent transcriptomic changes in the BM18 groups (intact versus
castrated versus replaced) (Figure 2A,E). Venn Euler diagrams illustrate androgen level-dependent
stromal gene expression modulation not only in the BM18 (Figure S2D and Table S1) but, also,
in the androgen-independent (in terms of tumor growth) LAPC9 model (Figure S2E,F and Table S1).
To identify the top-most significant AR-regulated stromal genes, we performed a differential expression
analysis of BM18 tumors (Figure 4A) from castrated hosts and compared it to BM18 intact (the replaced
tumors were not included here due to higher variability). Of the top-most variable genes, 50 were
highly upregulated in BM18 tumors (z-score >1) and downregulated upon castration (Figure 4A).
A differential expression analysis of LAPC9 tumors from castrated/replaced tumors versus intact
tumors revealed the top-most differentially regulated genes: the 27 most upregulated genes in intact,
which were downregulated in the castrated groups (Figure 4B). Among the 50 mouse genes that were
highly upregulated in the intact BM18, and significantly modulated by castration, were 23 genes
implicated in cell cycle/mitosis, 10 implicated in ECM and 3 related to spermatogenesis/hormone
regulation, according to the Gene Ontology terms (Figure 4C). Two of these genes, Tnc and Crabp1,
were also detected in the proteomic data (Figure 4C, highlighted in bold) and in both PDXs (Figure 4C,D,
highlighted in red). Among the 27 mouse genes that were highly upregulated in the intact LAPC9,
and significantly modulated by castration, seven genes were implicated in ECM/cell adhesion/smooth
muscle function, and 14 were implicated in non-smooth muscle function and metabolism based on
the Gene Ontology terms (Figure 4D). In the LAPC9 proteomic data, we detected 14 genes out of
the 27 to be expressed in the mouse fractions (Figure 4D, bold), indicative of potential functional
values. Of interest in potentially mediating tumor stroma extracellular interactions are a neural
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adhesion protein (CD56), implicated in cell–cell adhesion and migration by homotypic signaling,
as well as Tenascin C (Tnc), an extracellular protein that is found abundantly in the reactive stroma of
various cancer types, yet not expressed in normal stroma. Both genes were expressed at the protein
level, exclusively in the mouse compartment of the BM18 and LAPC9, at all states (intact, castrated
and replaced). Furthermore, Tnc was detected in both BM18 and LAPC9 at the transcriptional and
proteomic levels and was reactivated after 24 h of androgen replacement (Figure 4B), indicative of
AR-direct target gene modulation.
2.4. Cross Comparison of Stromal Transcriptome among Different PDXs Identifies ECM and Cell Adhesion
Pathways in the LAPC9 Androgen-Independent Model
To assess the similarity between the stromal transcriptome of the androgen-independent LAPC9
and the BM18, a differential expression analysis was performed. In a panel of the 50 top-most variable
genes comparing the tumors at their intact conditions, we identified several genes that follow the same
pattern of modulation in intact tumors (Figure 5A) and in castrated tumors (Figure 5B). Of interest were
the ECM-related genes downregulated in LAPC9 versus BM18; the Fibroblast Growth Factor receptor
(Fgfr4), elastin microfibril interface (Emilin3) and upregulated collagen type 2 chain a1 (Col2a1).
The differential expression of LAPC9 castrated versus BM18 castrated highlighted genes that were
identified in the analysis among LAPC9 castrated, replaced versus LAPC9 intact, such as Apelin (Apln),
Col2a1 and Tenascin C (Tnc).
To identify the biological processes ongoing in the LAPC9 compared to BM18, a pathway
analysis was performed on the differentially expressed murine genes of the LAPC9 versus the
BM18. Enrichment maps of the top 20 enriched GO biological pathways highly overlap pathways,
such as ECM, focal tadhesion and cell adhesion/migration in the intact and castrated LAPC9
(Figure S3A,B). Similarly, among the KEGG pathway sets, there was an enrichment of stroma
regulation (e.g., actin cytoskeleton, focal adhesion and cell adhesion) and bone and immune-related
processes (e.g., osteoclast differentiation) (Figure S3C–F and Table S2). The enrichment of cancer-related
pathways (e.g., PI3K/AKT, proteoglycans in cancer, pathways in cancer) was commonly found in the
LAPC9 intact and castrated stroma transcriptomes (Figure S3E,F and Table S2).
Given that genes activated in a castrated state might be indicative of androgen resistance
mechanism activation, we postulated that genes upregulated in the androgen-resistant LAPC9 over
the androgen-dependent BM18 might be relevant for understanding the aggressive phenotype of
LAPC9 and, therefore, of the advanced metastatic phenotype of similar tumors. One of those genes,
Tenascin, is an ECM protein that is produced at the (myo)fibroblasts that is virtually absent in normal
stroma in the prostate and other tissues and has been associated with the cancerous reactive stroma
response in different cancers. We interrogated the expression of Tnc in the RNA-Seq data and found
that it was highly upregulated in LAPC9 compared to BM18 both in intact (logFC 4.23, p < 0.001) and
among the castrated conditions (logFC 6.9, p < 0.001) (Figure 5C). However, in both models, the Tnc
levels significantly decreased upon castration (BM18, p < 0.001 and LAPC9, p < 0.05), indicating the
potentially AR-mediated regulation of Tnc expression. In LAPC9 tumors, the TNC protein is expressed
in the tumor-adjacent ECM and in the proximity of vessels (Figure 5D, intact and castrated) and
co-expressed by smooth muscle actin (αSMA)- and collagen type I-positive myofibroblasts (Figure 5E).
Instead, the intact BM18 tumors show TNC and collagen type I deposition in the ECM, but there is no
overlap with αSMA-positive myofibroblasts (Figure 5D,E, BM18 intact). Castrated BM18 tumors have
minimal TNC expression, found only in cells proximal to the remaining epithelial glands, yet with no
typical fibroblast/stromal morphology (Figure 5D,E, BM18 intact), suggesting an altered phenotype of
TNC upon androgen deprivation.
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Figure 3. Proteomic analysis of human (tumor) versus mouse (stroma) of BM18 and LAPC9 tumors.
(A) Experimental separation of human from mouse cell suspensions from fresh tumor isolations by
MACS mouse depletion sorting. Cell fractions from intact/replaced (n = 3 each), castrated (n = 4)
biological replicates were pooled into a single replicate (n = 1) to achieve an adequate cell number
for the proteomic analysis (1 × 106 cells). Protein lysates from the different fractions of BM18/LAPC9
(intact, castrated and replaced) were subjected to Tandem Mass Tag (TMT) labeling (all-mouse or
all-human samples were multiplexed in one TMT experiment each), followed by mass spectrometry.
(B) Detected peptides from human and mouse fractions were searched against a combined human and
mouse protein database. Number of species specific or shared proteins is indicated in different colors.
(C) KLK3 (PSA; Prostate Serum Antigen) protein levels (log2 normalized TMT signal sum values) in
human cell isolations (left) and in mouse cell isolations (right), and the protein sequence was predicted
as human-specific (spheres indicate Homo Sapiens sequence). Seven-up Ob-BMST signature markers
POSTN, PDGFRB and MCAM protein levels were absent in human cell isolations (left) and present in
mouse cell isolations (right), while all the protein sequences were mouse-specific (triangles indicate
Mus Musculus sequences).
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Figure 4. Differential expression analysis of the transcriptome indicates different expression profiles of
stromal genes as response to androgen deprivation. (A) Heatmap represents a differential expression
analysis of the most variable genes from the mouse transcriptome of BM18 castrated compared to BM18
intact tumors. Genes modulated by androgen deprivation due to castration in the up/downregulation
compared to intact tumors are indicated in red or blue colors, respectively. (B) Heatmap represents
Z-score of the differential expression analysis of most variable genes in the mouse transcriptome
of LAPC9 castrated (with and without androgen replacement) compared to LAPC9 intact tumors.
(C) Description of mouse genes found upregulated in BM18 intact tumors and the biological processes
they are involved in, according to the Gene Ontology (GO) terms. (D) Description of the mouse genes
found upregulated in LAPC9 intact tumors and the biological processes they are involved in, according
to the GO terms.
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Figure 5. Cross-comparison of LAPC9 versus BM18 suggests stromal gene Tenascin C expression
being associated with advanced PCa and regulated by androgen levels. (A) Heatmap represents the
differential expression analysis of the top 100 most variable genes from the mouse transcriptome of
LAPC9 intact tumors compared to BM18 intact tumors and (B) of LAPC9 castrated tumors compared
to BM18 castrated tumors. (A) Subset of genes in LAPC9 samples have zero counts, leading to the
same z-score, while the same genes are highly expressed in BM18 samples. (C) Tnc RNA expression
(log2CMP counts) in the stroma transcriptome. LogFC (fold change) enrichment of Tnc in LAPC9 over
BM18 is indicated. Ordinary two-way ANOVA with Tukey’s multiple comparison correction was
performed, p < 0.05 (*) and p < 0.0001 (****). (D) Tenascin protein expression and stromal specificity
assessed by immunohistochemistry in LAPC9 and BM18 tumors, both at the intact and castrated states.
Scale bars: 20 µm. (E) Tenascin protein (indicated in red) colocalization with stromal markers, smooth
muscle actin (αSMA, green) and collagen type I (gray) assessed by immunofluorescence in LAPC9 and
BM18 tumors, both at the intact and castrated states. DAPI marks the nuclei. Scale bars: 50 µm.
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2.5. Protein Expression of Tenascin and Its Interaction Partners
To assess whether the transcriptomic changes of Tnc in the PDX models corresponds to the
functional protein and, thus, a relevant role in bone metastatic PCa, we performed a proteomic analysis.
A mass spectrometry analysis of the human and mouse fractions indicated that the Tnc protein was
expressed specifically in the mouse (stromal) fractions in BM18 and LAPC9 (Figure 6A). The isoform
Tenascin X was also expressed at the protein level (Figure 6B). The interaction network of the mouse
protein Tnc is based on experimental observations and prediction tools (STRING) and consists of
laminins (Lamc1 and Lamb2); fibronectin (Fb1); integrins (Itga2, a7, a8 and a9) and proteoglycans
(Bcan and Vcan) (Figure 6C). The human interactome is less-characterized, yet most of the interactome
is conserved: laminins (LAMC1 and LAMB2); proteoglycans (NCAN and ACAN) and others such as
interleukin 8 (IL-8), BMP4, ALB and SDC4 (Figure 6D). However, integrin interaction-binding partners
in a human setting have not been confirmed. Given the importance of integrins for cell adhesion and
migration known to be found in mesenchymal/stromal and epithelial tumor cells, we focused on the
expression of human- and mouse-derived integrins. The ITGA9, ITGA6 and ITGA2 were all found
to be expressed in both the RNA-Seq and proteomic data (Figure 6E, ITGA6, respectively); however,
only the ITGA2 protein was specifically found in the human counterpart and not overlapping with the
mouse stroma (Figure 6F). Co-labeling both proteins indicated adjacent spatial localization with TNC
deposition in close proximity to ITGA2-positive epithelial cells (Figure 6G); however, whether those cell
populations acquired different properties compared to other epithelial cells has yet to be investigated.
Overall, the tumor ITGA2 and stromal Tnc is a potential molecular interaction, possibly part of the
dual cellular communication among a tumor and its microenvironment cellular types and ECM.
2.6. Stromal Tenascin Expression as a Prognostic Factor of Disease Progression in High-Risk PCa
The detection of key mouse stromal genes in PCa PDXs gives the opportunity to evaluate the
role and potential prognostic value of the human orthologs of these stromal genes. To validate the
localization and stromal specificity of TNC protein expression, we performed immunohistochemistry on
the primary PCa tissue sections. TNC is localized in the extracellular space (Figure 7A, primary cases).
Next, we evaluated the TNC expression in a tissue microarray of 210 primary prostate tissues,
part of the European Multicenter High Risk Prostate Cancer Clinical and Translational research
group (EMPaCT) [14–16] (Figure 7B–G). Based on the preoperative clinical parameters of the TMA
patient cases (Table 1, Table 2) and the D’Amico classification system [17], they represent intermediate
(clinical T2b or Gleason n = 7 and PSA >10 and ≤ 20) and high-risk (clinical T2c-3a or Gleason score
(GS) = 8 and PSA ≥ 20) PCa. The number of TNC-positive cells (Figure 7B) were quantified and
averaged for all cores (four cores per patient case) in an automated way, including tissue selection,
core annotation and equal staining parameters set. To investigate the association between the number
of TNC-positive cells and patient survival or disease progression, we calculated the optimal cut-point
for the number of TNC-positive cells by estimation of the maximally selected rank statistics [18].
Association between TNC-expressing cells and pT Stage indicated that the majority of cases cluster
towards stages 3a and 3b (Figure 7C). A multiple comparison test among all groups showed no
statistically significant association between the TNC expression and pathological stage (Table S3,
p > 0.05). The overall survival probability between two patient groups with, respectively, high and low
numbers of TNC-positive cells was indifferent (p = 0.29, Log-rank test) (Figure 7D). We focused on the
probability of TNC expression in primary tumors to be a deterministic factor for clinical progression
to local or metastasis recurrence. Clinical progression probability was higher in the TNC-low group
compared the TNC-high group (p = 0.04 *, Log-rank test) (Figure 7E). Next, we examined the clinical
progression in patients with pT Stage ≥3 (groups 3a, 3b and 4). The high T-Stage cases did separate
into two groups based on the TNC expression, with the TNC low-expressing group exhibiting earlier a
clinical progression (local or metastatic recurrence, p = 0.013 *, Log-rank test) (Figure 7F). The PSA
progression probability in patients with pT Stage ≥3 indicated an association trend of a TNC-low group
with earlier biochemical relapse events (p = 0.07, Log-rank test) (Figure 7G). Similarly, the TNC-low
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group correlated with a higher probability for PSA progression after radical prostatectomy among
cases with carcinoma-containing (positive) surgical margins (Figure S4A, p = 0.031 *, Log-rank test) or
positive lymph nodes (Figure S4B, p = 0.092, Log-rank test). A low number of TNC-expressing cells
coincides with a poor prognosis in terms of metastasis progression, similarly to its downregulation
upon castration in the bone metastasis PDXs (Figure 4B) based on the RNA-Seq analysis. To further
evaluate the clinical relevance of this finding, in multiple clinical cohorts with available transcriptomic
data and clinical information, a CANCERTOOL analysis was performed [19]. Similar to the protein
TMA data (Figure 7), the TNC mRNA levels were significantly downregulated during the disease
progression from primary to PCa metastasis, compared to the expression in the normal prostatic tissues
in all five datasets tested (Figure 8A). The TNC expression shows a pattern of inverse correlations,
with the Gleason score among GS6 to GS9; however, it significantly discriminated patient groups for the
Gleason score in one out of three datasets tested (Figure 8B, TCGA dataset * p = 0.049, Glinsky p = 0.06,
Taylor p = 0.192), with the highest expression found in a high GS10 group and indifferent among
GS6-GS9. A disease-free survival analysis indicated that a low TNC expression is associated with a
worse prognosis based on the Glinsky dataset (Q1 Glinsky et al. [20], * p = 0.02), while no statistically
significant association was observed in the Taylor and TCGA dataset (Figure 8C). Overall, the TNC
expression in tumor samples, both at the RNA and protein levels, becomes progressively less abundant
in primary and metastasis PCa specimens, while a low TNC expression is significantly associated with
the disease progression and poor disease-free survival (DFS) outcome.
2.7. Stroma Signatures from Androgen-Dependent and -Independent States Correlate with Disease Progression
In order to comprehensively map the stroma responses related to the disease severity,
we analyzed the stroma gene signature lists associated to androgen dependency and aggressive
androgen-independent states. The stroma signatures are categorized in clusters (C1–C4, Table S4)
based on a differential expression analysis (Figures 4 and 5): C1 (50 highly upregulated genes in BM18
intact that get downregulated upon castration), C2 (27 highly upregulated genes in LAPC9 intact that
get downregulated upon castration), C3 (32 highly upregulated genes in LAPC9 intact compared to
BM18 intact) and C4 (24 highly upregulated genes in LAPC9 castrated compared to BM18 intact).
Clusters C1 and C2 aim to identify the most responsive genes to androgen deprivation. C3 and C4
are designated to identify the genes/pathways enriched in the stroma of castration-resistant prostate
cancer (CRPC) compared to the androgen-dependent tumor model. The TNC gene was among the
signature list: C1, C3 and C4. The prognostic potential of the C1-C4 signatures in comparison to the
bone signature Ob-BMST was tested on the TCGA cohort based on the Gleason score, gene expression
and outcome data (Figure 9 and Table S5). The high signature scores of Ob-BMST, C1, C2 and C4 had
statistically significant positive correlations with the high GS groups (Figure 9A, Ob-BMST and C1
(p < 0.001), C2 and C4 (p < 0.01)). In terms of gene expression, the C1 signature was significantly higher
in primary tumors versus normal tissues (Figure 9B, p < 0.001), while the C2, C3 and C4 have lower
signature scores in the tumor samples compared to normal (Figure 9B, C2 and C3 (p < 0.001) and C4
(p < 0.01)). Kaplan-Meier plots of progression-free survival (PFS) stratified as the bottom 25% (Q1),
middle 50% (Q2 and 3) and top 25% (Q4) showed significant correlations among the high signature
scores (Q4) of the C1 gene set and PFS (Figure 9C, p < 0.001), while none of the other gene lists showed
significant correlations.
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Figure 6. Tenascin C and its predicted interaction partners analyzed by mass spectrometry. (A) Tenascin
C (TNC) and (B) alternative isoform Tenascin X (TNXB) protein relative abundance (log2 ratios;
single replicates per sample from a pool of n = 3 to 4) in human cell isolations (left) and present in
mouse cell isolations (right). The variance stabilization normalization (vsn)-corrected TMT reporter ion
signals were normalized by the intact conditions of either BM18 or LAPC9. The protein sequences
were predicted as mouse-specific (green). (C) Protein interaction network of the mouse TNC protein
based on the STRING association network (https://string-db.org/). (D) Protein interaction network of
the human TNC protein based on the STRING association network https://string-db.org/. (E) Predicted
TNC-binding partner integrin A6 (ITGA6) was detected by mass spectrometry in both the human and
mouse protein lysates and matching the organism-specific protein sequence based on the bioinformatics
analysis (red for human and green for mouse). (F) Predicted TNC-binding partner integrin A2
(ITGA2) was detected by mass spectrometry, specifically in the human protein lysates, and matched the
human-specific protein sequence. (G) Spatial localization of the Tenascin protein (TNC, indicated in
red) and integrin A2 (ITGA2, green) assessed by immunofluorescent co-labeling in LAPC9 intact and
castrated tumors. DAPI marks the nuclei. Scale bars: 50 µm.
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Figure 7. TNC protein expression is a negative metastasis prognostic factor in primary, high-risk PCa.
(A) Validation of the protein expression and stromal specificity of TNC by immunohistochemistry in
primary PCa cases. (B) Representative cases of TNC staining on primary PCa Tissue Microarray (TMA)
from European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT).
(C) TNC expression levels in terms of the no. of positive cells in the pT Stage classification. Statistical
multiple comparison test, the Wilcoxon rank sum test, was performed; p > 0.05 (D) Overall survival
probability in patient groups of TNC-high and TNC-low (no. of positive, TNC-expressing cells)
(p = 0.29, ns—non significant). Average value represents the mean of four cores per patient case.
(E) Clinical progression to the local recurrence or metastasis probability in patient groups of TNC-high
and TNC-low expressions (p = 0.04 and * < 0.05). (F) Clinical progression to the local recurrence or
metastasis probability among patients of pT Stages 3a, 3b and 4 based on TNC-high and TNC-low
expressions (p = 0.013 and * < 0.05). (G) PSA progression probability among patients of pT Stages 3a,
3b and 4 based on the TNC-high and TNC-low expressions (p = 0.074, ns).
Cancers 2020, 12, 3786 15 of 29
Table 1. Clinical parameters of the EMPaCT TMA patient cases.
Descriptive
Statistics Age at Surgery PSA at Surgery
PSA Progression Time
(Months)
Clinical Progression
Time (Months)
Min 43 20 1 1
1st quartile 62 25.33 29.5 40.5
Median quartile 67 36.99 63.5 75.5
Mean quartile 66.18 50.56 63.47 70.89
3rd quartile 71 61.9 90 95.75
Max quartile 81 597 151 153
Table 2. Pathological staging, PSA and Clinical Progression of the EMPaCT TMA patient cases.
PSA
Progression
Clinical
Progression
Pathological Staging (No. of Patient Cases)
2a 2b 3a 3b 4
no no 6 15 37 63 26
yes 0 0 0 1 0
yes no 0 5 7 11 7
yes 1 7 9 9 6
To further assess the prognostic performance of the signatures, we correlated the C1-C4 gene
signatures with PCa-specific stroma signatures identified by Tyekucheva et al. [7] and Mo et al. [21]
(Table S4) across two cohorts containing both primary and metastatic PCa that were used [22,23]. The C3
and C4 showed the strongest linear correlations with the Tyekucheva and the Mo_up (upregulated
in metastases) signatures when tested across the Grasso dataset (Figure S5A, r > 0.64), while the C4
signature also had positive correlations when tested across the Taylor et al. dataset (Figure S5B, r > 0.6).
The C1 signature did not significantly correlate with the gene lists tested (Figure S5A, C1 p > 0.05).
The low signature score of the C2 and C3 were significantly associated with metastatic disease
progression (Figure S5B, p < 0.001) in both cohorts tested, and C4 showed a similar pattern (Figure S5B,
C4 p = 0.062). A common pattern of the stroma signatures is a similar or enriched signature score
at the primary stage compared to benign/normal tissue, and lower/depleted signature scores at the
metastasis stage (Figure S5C,D; C2, C3 and C4, Tyekucheva and Mo and Figure 9B; C2-C4). Only a
significant correlation with the Gleason score was observed by the C1 signature list, with a high
signature score found at the high GS patient groups (Figure S5E, p ≤ 0.001), which is in concordance to
the linear correlation with metastatic disease in all clinical cohorts tested (Figure S5C,D, p ≤ 0.001 and
Figure 9, TCGA).
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Figure 8. TNC RNA expression is inversely correlated with the disease progression, Gleason score and
survival. (A) Violin plots depicting the expression of TNC among nontumoral (N), primary tumor (PT)
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and metastatic (M) PCa specimens in the indicated datasets. The Y-axis represents the Log2-normalized
gene expression (fluorescence intensity values for microarray data or sequencing read values obtained
after gene quantification with RNA-Seq Expectation Maximization (RSEM) and normalization using
the upper quartile in case of RNA-seq). An ANOVA test is performed in order to compare the mean
gene expression among two groups (nonadjusted p-value), obtained by a CANCERTOOL analysis.
(B) Violin plots depicting the expression of TNC among PCa specimens of the indicated Gleason grade
in the indicated datasets. The Gleason grades are indicated as GS6, GS7, GS8, GS8+9, GS9 and GS10.
An ANOVA test is performed in order to compare the mean among groups (nonadjusted p-value),
obtained by a CANCERTOOL analysis. (C) Kaplan-Meier curves representing the disease-free survival
(DFS) of patient groups selected according to the quartile expression of TNC. Quartiles represent ranges
of expression that divide the set of values into quarters. Quartile color code: Q1 (Blue), Q2 plus Q3
(Green) and Q4 (Red). Each curve represents the percentage (Y-axis) of the population that exhibits a
recurrence of the disease along the time (X-axis, in months) for a given gene expression distribution
quartile. Vertical ticks indicate censored patients. Quartile color code: Q1 (Blue), Q2 plus Q3 (Green)
and Q4 (Red). A Mantel-Cox test is performed in order to compare the differences between curves,
while a Cox proportional hazards regression model is performed to calculate the hazard ratio (HR)
between the indicated groups. Nonadjusted p-values are shown. Analysis obtained by CANCERTOOL.
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Figure 9. Stroma signatures identified from bone metastatic PDXs as prognostic biomarkers in primary
PCa. (A) Violin plots showing Gene Set Variation Analysis (GSVA) signature scores of the Ob-BMST,
C1-C4 gene sets, stratified by Gleason score from the TCGA cohort. Box-and-whisker plots illustrating
median (midline), inter-quartile range (box), with the whiskers extending to at most 1.5 IQR from
the box. Outliers beyond the range of the whiskers are illustrated as dots. P-values computed by
Spearman correlation tests. (B) Violin plots showing GSVA signature scores of the Ob-BMST and C1-C4
gene sets stratified by sample types (NT: nontumor and TP: primary tumor) from the TCGA cohort.
Box-and-whisker plots illustrating the median (midline) and interquartile range (box), with the whiskers
extending to at most 1.5 IQR from the box. Outliers beyond the range of the whiskers are illustrated as
dots. P-values computed by Mann-Whiney U tests. (C) Kaplan-Meier plots of progression-free survival
(PFS) stratified as the bottom 25% (Q1), middle 50% (Q2 and 3) and top 25% (Q4) of the signature
scores of the Ob-BMST and C1-C4 gene sets. P-values and hazard ratios computed by Cox proportional
hazard regression.
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3. Discussion
The role of the microenvironment upon cancer formation and progression to metastasis is
supported by numerous studies [24,25]; however, the current knowledge is not sufficient to reconstruct
the chain events from primary to secondary tumor progression. The normal stroma microenvironment
is considered to halt tumor formation; however, after interactions with tumor cells, it also undergoes a
certain “transformation” at the transcriptomic, and even at the genetic, levels [26–29]. The processes
by which PCa tumor cells affect stroma and, in turn, stroma impacts primary PCa tumor growth or
metastasis are complex and remain largely unclear.
We utilized well-established bone metastasis PDX models, which can be propagated
subcutaneously and have different aggressiveness in terms of androgen dependency: the CRPC model
LAPC9 representing complete androgen-independent advanced disease [30] and the BM18 that mimics
human luminal PCa [31,32] and uniquely retains androgen sensitivity, typically seen in the primary and
treatment-naïve stages. The androgen-independent stem cell populations that survive castration are
well characterized in both models [31,33,34]; yet, the contribution of the stroma in those district tumor
phenotypes has not been investigated. In vivo PDX models grafted in immunocompromised mice,
although they lack the complexity of a complete immune system, represent the stroma compartment
(endothelial cells, smooth muscle cells, myofibroblasts and cancer-associated fibroblasts). Due to the
subcutaneous growth of BM PCa PDXs, the human stroma is replaced by mouse-infiltrating stromal
cells and vasculature [35,36]. Mouse cell infiltration allows the discrimination of organism-specific
transcripts, human-derived transcripts representing the tumor cells and mouse-derived transcripts
representing the mouse stroma compartment. Using next-generation RNA-Seq, MACS-based human
and mouse cell sorting, mass spectrometry and organism-specific reference databases, we have
identified the tumor-specific (human) from the stroma-specific (mouse) transcriptomes and proteomes
of bone metastasis PCa PDXs. The dynamics of AR signaling in the stroma are best represented in
an in vivo setting [11]; therefore, to specifically examine the stroma changes dictated by PCa cells,
we subjected the PDXs in androgen and androgen-deprived conditions. By imposing this selection
pressure, we could identify androgen-dependent gene expression patterns.
We demonstrated that the human (tumor), as well as the mouse (stroma), transcriptomes follow
androgen-dependent transcriptomic changes in the BM18 groups (intact versus castrated versus
replaced). Despite the androgen-independent tumor growth of LAPC9, at the gene expression
level, the LAPC9 tumor cells do follow AR-responsive patterns (human transcriptomes). However,
the principal component analysis showed that, although castrated and replaced LAPC9 groups
separate adequately based on the human transcriptome, they appear to have overall uniform
stromal transcriptomes.
We report that transcriptomic mechanisms linked to osteotropism were conserved in bone
metastatic PDXs, even in nonbone environments, and differential stroma gene expressions are induced
by different tumors, indicating the tumor specificity of stroma reactivity. The Ob-BMST signature of all
seven genes (Aspn, Pdgrfb, Postn, Sparcl1, Mcam, Fscn1 and Pmepa1), which were upregulated in bone
stroma previously identified [5], were indeed expressed in both BM18 and LAPC9 PDXs, specifically
in the mouse RNA-Seq and, also, expressed at the protein level, as identified by mass spectrometry.
The gene expression modulation of mouse stroma is, ultimately, an important evidence of the effects of
tumor cells in their microenvironment, where they induce favorable conditions for their growth.
The differential expression analysis of the LAPC9 stroma signature from intact, castrated and
replaced hosts highlighted the most significantly variable genes, which were modulated by androgen
levels, despite the androgen-independent tumor growth phenotype. Focusing on the genes that were
highly activated in intact but strongly modulated by castration, we categorized these genes based
on Gene Ontology terms. We found that LAPC9 stromal genes were ECM remodeling components
and genes involved in smooth muscle function or even in striated muscle function. Of interest are
CD56, Tnc and Flnc. Among the BM18 most abundant stromal transcripts are genes involved in cell
cycle regulation and cell division. Interrogating the differences among the two models, we focused
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on the transcriptome of LAPC9 normalized versus the less aggressive, androgen-dependent BM18.
In particular, Tnc is expressed in both PDXs, higher in LAPC9, yet downregulated upon castration,
suggesting a direct AR gene regulation. The differential expression analysis among both the PDXs
after castration indicated that Tnc is upregulated more in LAPC9 than BM18, suggesting an association
with disease aggressiveness. Genes that become upregulated in castrated conditions are likely to be
linked to androgen resistance; thus, we studied Tnc for its potential role in metastasis progression.
TNC is an extracellular glycoprotein absent in normal prostates and postnatally silenced in
most tissues. TNC is re-expressed in reactive stroma in human cancers, and there is evidence of its
expression in low-grade tumors (Gleason 3) of human PCa [37] and, possibly, already activated at
the prostatic intraepithelial neoplasia (PIN) stage [38,39]. In particular, high molecular weight TNC
isoforms are expressed in cancer due to alternative mRNA splicing [38]. We examined whether an
abundance of TNC-positive cells in primary PCa TMA can predict the metastatic progression and
overall survival (12 years follow-up after radical prostatectomy). A high number of TNC-positive
cells did not correlate with the overall survival or histological grade, in agreement with previous
data [38]. The PSA progression after radical prostatectomy occurred earlier in the TNC-low group
compared to the TNC-high group when high stage cases (pT ≥ 3), surgical margin-positive or lymph
node-positive cases were investigated. In terms of clinical progression, the TNC-low group in the total
number of cases and among the high stage (pT ≥ 3) cases showed a worse prognosis in terms of local
recurrence/metastasis. This finding is in contrast to the study of Ni et al., showing that high levels of
TNC are significantly linked to lymph node metastasis and the clinical stage [40] but in agreement
with another study that reported a weak TNC expression in high-grade PCa [39]. No low-risk cases or
metastasis tissues were used in our study, and we focused on TNC-producing cells, not the overall
TNC expression in the matrix. Therefore we can only conclude that the TNC is indeed expressed
in intermediate- and high-risk primary PCa as assessed at the preoperative diagnosis based on the
D´Amico criteria [17] and that a high number of TNC-positive cells is inversely correlated with
clinical progression.
More evidence points to the direction that the TNC might be degraded upon local recurrence in
lung cancer [41,42], while high TNC is found in lymph and bone metastases sites [38] or even in certain
types of bone metastasis [43]. In the TMA of PCa bone metastasis, San Martin et al. demonstrated
a high TNC expression in trabeculae endosteum, the site of osteoblastic metastasis, and yet, a low
TNC expression in the adjacent bone marrow sites [43]. Osteoblastic PCa cell lines proliferate rapidly
in vitro and adhere to TNC protein, while osteolytic PC3 or lymph node-derived PCa lines do not
show this phenotype, suggesting an association of TNC with osteoblastic but not osteolytic metastases.
One of the ligands of TNC highly upregulated in VCap cells was α9 integrin, which binds directly
TNC and a modulate expression of collagen [43], providing evidence for TNC-integrins in human
PCa. Our RNA-Seq data indicate, also, the expression of α9 integrin, along with α6 and α2, and based
on the proteomic human–mouse separation, we found integrin α2 to be the only one human-specific
and, thus, tumor-specific for the PDXs used in this study. Although the molecular mechanism among
TNC-ITGA2 should be further characterized, evidence on the correlation among α2 and α6 expressions
in primary PCa and bone metastasis occurrence has been previously reported [44].
The reactivation of TNC expression is relevant for reactive stroma regulation, while TNC
downregulation might be relevant for recurrence or metastasis initiation, which remains to be further
investigated. Indeed, TNC is known to have pleiotropic functions in different cellular contexts,
with both autocrine TNC expression in tumor cells and paracrine TNC from stroma in different stages
of metastasis [45]; however, the cellular source of TNC in primary PCa was not addressed in our
study. Our data demonstrate that androgens regulate stromal TNC expression, evident by the reduced
TNC expression upon castration (even in the castration-resistant LAPC9) and immediate increased
expression upon androgen replacement; thus, the TNC expression should be further evaluated in CRPC
samples. Genomic amplification in the TNC gene associated with highly aggressive neuroendocrine
PCa occurrence [46]. In a multi-omics approach study, the TNC protein was one of the panels of four
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markers detected in preoperative serum samples and, collectively, predict the biochemical relapse
events with high accuracy [47].
In summary, we identified the stroma signature of bone metastatic PDXs, and by analyzing
androgen-dependent versus androgen-independent tumors, we could demonstrate that the
tumor-specific stroma gene expression changes. We could show that there are AR-regulated stromal
genes modulated upon castration, even in the androgen-independent, for tumor growth, like the
LAPC9 model. The osteoblastic bone metastasis stromal seven-gene signature was induced in the
mouse-derived stroma compartment of BM18 and LAPC9, indicating conserved tumor mechanisms
that can induce the transcriptomic “transformation” of mouse-infiltrating stroma (even in subcutaneous
sites) to bone microenvironment-like stroma. The prognostic value of stroma signatures has been also
demonstrated by another study utilizing PDXs associated with the metastasis prognosis from different
lesions from a single PCa case and demonstrated the strong predictability of 93-gene stroma signatures
to metastasis phenotypes in different clinical cohorts [21]. We identified androgen-dependent Tenascin
C expression in the stroma of PDX models, which is downregulated in the conditions mimicking
an aggressive disease (upon castration), similarly to the high clinical progression probability of a
low TNC group in the primary PCa TMA. The higher stromal Tnc mRNA levels in the aggressive
LAPC9 compared to BM18 may suggest that it would be relevant to examine the TNC mRNA and
protein expressions in human bone metastasis or ideally matched primary metastasis cases in order
to understand the kinetics of TNC in terms of disease progression. Given that TNC expression was
found elevated from 0% in benign prostatic hyperplasia (BPH) stroma to 47% in tumor-associated
stroma [29], its detection in circulation [47] and its immunomodulatory role [48] indicate TNC as a
promising drug target and disease-determining factor. The TNC clinical progression predictive value
performs best in an earlier stage, low-risk PCa, while our data show that, in high-risk PCa, a low
number of TNC-producing cells were associated with poor prognosis, possibly due to changes in tissue
remodeling and, thus, variable TNC levels.
These findings were corroborated by the external clinical cohorts of patients [22,23,49,50]
(Grasso et al., Lapointe et al., Taylor et al. and Varambally et al.) showing that TNC levels are
downregulated during the disease progression from primary to metastasis. Based on differential
expression analysis, we identified clusters of stroma signatures based on androgen-(in)dependent
responses (C1-C4). TNC is a component of the C1, C3 and C4 signatures. In silico validation of the
identified prostate cancer-specific stroma expression signatures on additional clinical cohorts showed
the potential for patient stratification. A common feature of the majority of the four clusters of gene lists
tested indicated a low stroma signature score in the advanced disease stage and a correlation with disease
progression (metastasis). This was the case also for previously published stroma signatures [7,21]
(Tyekucheva et al. 2017 and Mo et al. 2017) when compared to our gene sets, perhaps due to the
reduced stroma content in low-differentiated, advanced PCa stage. The signature most related to the
androgen-independent stage (C4) positively correlated with the Gleason score in primary tissues from
TCGA but not in the metastatic cohort of the Taylor dataset. Instead, we identified a 50-gene stroma
signature (C1, derived from the most androgen-responsive stroma genes), which positively correlates
with the disease progression, Gleason score and poor prognosis survival, consistently on all patient
cohorts evaluated, both the primary and metastasis stages.
The regime that a metastatic, stroma-specific molecular signature may be detectable in the PCa
site either prior to or during metastasis will most likely require not a single marker approach but a
combination of biochemical and histological markers, taking into consideration dual tumor–stroma
interactions in order to provide prognostic tools for improved patient stratification after the initial PCa
diagnosis and preventive surveillance for metastasis risk.
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4. Materials and Methods
4.1. Tumor Sample Preparation and Xenograft Surgery Procedure
LAPC9 and BM18 xenografts were maintained subcutaneously in 6-week-old CB17 SCID male
mice under anesthesia (Domitor® 0.5 mg/kg, Dormicum 5 mg/kg and Fentanyl 0.05 mg/kg). All animal
experiments were approved by the Ethical Committee of Canton Bern (animal licenses BE55/16 and
BE12/17). Castration was achieved by bilateral orchiectomy. For androgen replacement, testosterone
propionate dissolved in castor oil (86541-5G, Sigma-Aldrich, Buchs, Switzerland) was administered by
single subcutaneous injection (2 mg per dosage, 25-G needle).
4.2. RNA Isolation from Tissue Samples
Tissue RNA was extracted using the standard protocol of Qiazol (79306, Qiagen AG,
Hombrechtikon, Switzerland) tissue lysis by TissueLyser (2 min, 20 Hz). Quality of RNA was assessed
by Bioanalyzer 2100 (Agilent Technologies, Basel, Switzerland). RNA from formalin-fixed-paraffin
embedded (FFPE) material was extracted using the Maxwell® 16 LEV RNA FFPE Purification Kit
(AS1260, Promega AG, Dübendorf, Switzerland).
4.3. RNA Sequencing
RNA extracted from BM18, and LAPC9 whole PDX tumor extracts (300 ng) were subjected
to RNA sequencing. Specimens were prepared for RNA sequencing using Tru-Seq RNA Library
Preparation Kit v2 or riboZero, as previously described [51]. RNA integrity was verified using the
Bioanalyzer 2100 (Agilent Technologies, Basel, Switzerland). Complementary cDNA was synthesized
from total RNA using Superscript III reverse transcriptase (18080093, Thermo Fisher Scientific, Basel,
Switzerland). Sequencing was then performed on GAII, Hi-Seq 2000 or Hi-Seq 2500. The sample
preparation was performed according to the protocol “NEBNext Ultra II Directional RNA Library Prep
Kit (NEB #E7760S/L, Illumina GmbH, Zürich, Switzerland). Briefly, mRNA was isolated from total
RNA using the oligo-dT magnetic beads. After fragmentation of the mRNA, a cDNA synthesis was
performed. This was used for ligation with the sequencing adapters and PCR amplification of the
resulting product. The quality and yield after sample preparation was measured with the Fragment
Analyzer. The size of the resulting products was consistent with the expected size distribution (a broad
peak between 300–500 bp). Clustering and DNA sequencing using the NovaSeq6000 was performed
according to manufacturer’s protocols. A concentration of 1.1 nM of DNA was used. Image analysis,
base calling and quality check was performed with the Illumina (Illumina GmbH, Zürich, Switzerland)
data analysis pipeline RTA3.4.4 and Bcl2fastq v2.20.
Sequence reads were aligned using STAR two-pass to the human reference genome GRCh37 [52]
and mouse reference genome GRCm38. Gene counts were quantified using the “GeneCounts” option.
Per-gene counts-per-million (CPM) were computed and log2-transformed, adding a pseudo-count
of 1 to avoid transforming 0. Genes with log2 CPM <1 in more than three samples were removed.
Differential expression analysis was performed using the edgeR package [53]. Normalization was
performed using the “TMM” (weighted trimmed mean) method, and differential expression was
assessed using the quasi-likelihood F test. Genes with false discovery rate FDR <0.05 and >2-fold were
considered significantly differentially expressed. RNA-Seq Expectation Maximization (RSEM) was
used to obtain TPM (transcripts per million) counts.
Pathway analysis (over-representation analysis) was performed using clusterProfiler R package [54]
for Gene Ontology biological processes and KEGG. For Venn Euler diagram analysis, expressed genes
were identified using the zFPKM transformation [55]. For the comparison between the states of the
BM18 and LAPC9 models, genes were considered expressed if a gene had zFPKM values > −3 [55] in
all samples.
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4.4. Signature Validation on TCGA and Other Publically Available Datasets
TCGA gene expression, Gleason scores and outcome data were obtained from the
PanCanAtlas publications supplemental data site (https://gdc.cancer.gov/about-data/publications/
pancanatlas) [56,57]. For the Gene Set Variation Analysis (GSVA) analysis, RSEM expected counts in the
upper quartile normalized to 1000 (i.e., the same normalization as TCGA) were used for BM18/LAPC9
gene expression. Mouse genes in gene signature lists were mapped to human homologs using the
biomaRt R package (Table S5), using the “mmusculus_gene_ensembl” dataset and selecting only
homologs with hsapiens_homolog_orthology_confidence = 1. Signature scores were calculated using
the GSVA R package using the GSVA method [58].
Validation of the C1-C4 stroma signatures on publicly availably cohorts was performed
using the Taylor (GSE21034) and the Grasso (GSE35988) datasets. Gene expression and sample
information, including Gleason scores, were obtained via the GEOquery Bioconductor package.
Mouse genes in the C1-C4 gene signature lists were mapped to human homologs using the
biomaRt R package, using the “mmusculus_gene_ensembl” dataset and selecting only homologs with
hsapiens_homolog_orthology_confidence = 1. Other gene sets are either human genes or include info
on human homologs. Signature scores were calculated using the GSVA R package using the GSVA
method [58].
4.5. Tissue Dissociation and MACS
Tumor tissue was collected in a basis medium (advanced Dulbecco Modified Eagle Medium F12
serum-free medium (12634010, Thermo Fisher Scientific, Basel, Switzerland) containing 10-mM Hepes
(15630080, Thermo Fisher Scientific, Basel, Switzerland), 2-mM GlutaMAX supplement (35050061,
Thermo Fisher Scientific, Basel, Switzerland) and 100 µg/mL Primocin (ant-pm-1, InVivoGen, LabForce
AG, Muttenz, Switzerland). After mechanical disruption, the tissue was washed in the basis medium
(220 relative centrifugal force (rcf), 5 min) and incubated in the enzyme mix for tissue dissociation
(collagenase type II enzyme mix (17101-015, Gibco, Thermo Fisher Scientific, Basel, Switzerland)
5 mg/mL dissolved in the basis medium and DNase: 15 µg/mL (10104159001, Sigma-Aldrich, Buchs,
Switzerland) and 10-µM Y-27632-HCl rock inhibitor (S1049, Selleckchem, Zürich, Switzerland). Enzyme
mix volume was adjusted so that the tissue volume did not exceed 1/10 of the total volume, and tissue
was incubated at 37 ◦C for 1 to 2 h, with mixing every 20 min. After the digestion of large pieces
was complete, the suspension was passed through a 100-µm cell strainer (21008-950, Falcon®,
VWR International GmbH, Dietikon, Switzerland) attached to a 50-mL Falcon tube, then using a rubber
syringe to crash tissue against the strainer and wash in 5-mL basic medium (220 rcf, 5 min). Cell pellet
was incubated in 5-mL precooled red blood cell lysis buffer (150-mM NH4Cl, 10-mM KHCO3 and
0.1-mM EDTA), incubated for 10 min and washed in equal volume of basis medium, followed by
centrifugation (220 rcf, 5 min). Pellet was resuspended in 2–5 mL accutase™ (StemCell Technologies,
07920), depending on the sample amount; biopsies versus tissue and incubated for 10 min at room
temperature. The cell suspension was passed through a 40-µm pore size strainer (21008-949, Falcon®,
International GmbH, Dietikon, Switzerland), and the strainer was washed by adding 2 mL of accutase
on the strainer. Single-cell suspension was counted to determine the seeding density and washed
in 5 mL of basis medium and spun down 220 rcf, 5 min. Magnetic cell sorting was performed to
separate purified human versus mouse cell fractions using the Mouse Cell Depletion Kit (130-104-694,
Miltenyi Biotek, Solothurn, Switzerland). For the proteomic experiments, cell fractions from tumor
tissues (n = 3 to 4 per condition) were pooled together in order to suffice for 106 cells, representing one
technical replicate per sample.
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4.6. Proteomics
4.6.1. Sample Preparation
Approx. 106 cell pellets (n = 1 technical replicate per condition deriving from n = 3 to 4 biological
replicate samples) were resuspended in 50 µL PBS following the addition of 50 µL 1% SDS in
100-mM Hepes/NaOH, pH 8.5 supplemented with protease inhibitor cocktail EDTA-free (11836170001,
Sigma-Aldrich, Buchs, Switzerland). Samples were heated to 95 ◦C for 5 min, transferred on ice,
and benzonase (71206-3, Merck AG, Zug, Switzerland) was added to degrade DNA at 37 ◦C for 30 min.
Samples were reduced by the addition of 2 µL of a 200-mM DTT solution in 200-mM Hepes/NaOH,
pH 8.5 and, subsequently, alkylated by the addition of 4 µL of a 400-mM chloroacetamide (CAA,
#C0267, Sigma-Aldrich, Buchs, Switzerland) solution in 200 mM Hepes/NaOH, pH 8.5. Samples were
incubated at 56 ◦C for 30 min. Access CAA was quenched by the addition of 4 µl of a 200-mM DTT
solution in 200 mM Hepes/NaOH, pH 8.5. Lysate were subjected to an in-solution tryptic digest
using the single-pot solid phase-enhanced sample preparation (SP3) protocol [59,60]. To this end,
20 µL of Sera-Mag Beads (#4515-2105-050250 and 6515-2105-050250, Thermo Fisher Scientific, Basel,
Switzerland) were mixed, washed with H2O and resuspended in 100 µL H2O. Two microliters of
freshly prepared bead mix and 5 µl of an aqueous 10% formic acid were added to 40 µL of lysates to
achieve an acidic pH. Forty-seven microliters of acetonitrile were added, and samples were incubated
for 8 min at room temperature. Beads were captured on a magnetic rack and washed three times
with 70% ethanol and once with acetonitrile. Sequencing grade-modified trypsin (0.8 µg; V5111,
Promega AG, Dübendorf, Switzerland) in 10 µL 50 mM Hepes/NaOH, pH 8.5 were added. Samples
were digested overnight at 37 ◦C. Beads were captured and the supernatant transferred and dried
down. Peptides were reconstituted in 10 µL of H2O and reacted with 80 µg of TMT10plex (#90111,
Thermo Fisher Scientific, Basel, Switzerland) [61] label reagent dissolved in 4 µL of acetonitrile for 1 h at
room temperature. Excess TMT reagent was quenched by the addition of 4 µL of an aqueous solution
of 5% hydroxylamine (438227, Sigma-Aldrich, Buchs, Switzerland). Mixed peptides were subjected to
a reverse-phase clean-up step (OASIS HLB 96-well µElution Plate, 186001828BA, Waters Corporation,
Milford, MA, USA) and analyzed by LC-MS/MS on a Q Exactive Plus (Thermo Fisher Scientific, Basel,
Switzerland), as previously described [62].
4.6.2. Mass Spectrometric Analysis
Briefly, peptides were separated using an UltiMate 3000 RSLC (Thermo Scientific, Basel,
Switzerland) equipped with a trapping cartridge (Precolumn; C18 PepMap 100, 5 Lm, 300 Lm i.d. × 5 mm,
100 A◦) and an analytical column (Waters nanoEase HSS C18 T3, 75 Lm × 25 cm, 1.8 Lm, 100 A◦). Solvent A:
aqueous 0.1% formic acid and Solvent B: 0.1% formic acid in acetonitrile (all solvents were of LC-MS
grade). Peptides were loaded on the trapping cartridge using solvent A for 3 min with a flow of
30 µL/min. Peptides were separated on the analytical column with a constant flow of 0.3 µL/min
applying a 2 h gradient of 2–28% of solvent B in A, followed by an increase to 40% B. Peptides
were directly analyzed in positive ion mode, applied with a spray voltage of 2.3 kV and a capillary
temperature of 320◦C using a Nanospray-Flex ion source and a Pico-Tip Emitter 360 Lm OD × 20 Lm
ID;, 10 Lm tip (New Objective, Littleton, MA, USA). MS spectra with a mass range of 375–1.200 m/z
were acquired in profile mode using a resolution of 70,000 (maximum fill time of 250 ms or a maximum
of 3 × 106 ions (automatic gain control, AGC)). Fragmentation was triggered for the top 10 peaks with
2–4 charges on the MS scan (data-dependent acquisition), with a 30 s dynamic exclusion window
(normalized collision energy was 32). Precursors were isolated with a 0.7 m/z window and MS/MS
spectra were acquired in profile mode with a resolution of 35,000 (maximum fill time of 120 ms or an
AGC target of 2 × 105 ions).
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4.6.3. Raw MS Data Analysis
Acquired data were analyzed using IsobarQuant [63] and Mascot V2.4 (Matrix Science, Chicago,
IL, USA) using either a reverse-UniProt FASTA Mus musculus (UP000000589) or Homo sapiens
(UP000005640) database. Moreover, a combined database thereof was generated and used for the
analysis. These databases also included common contaminants. The following modifications were
taken into account: Carbamidomethyl (C, fixed), TMT10plex (K, fixed), Acetyl (N-term, variable),
Oxidation (M, variable) and TMT10plex (N-term, variable). The mass error tolerance for full-scan MS
spectra was set to 10 ppm and for MS/MS spectra to 0.02 Da. A maximum of 2 missed cleavages were
allowed. A minimum of 2 unique peptides with a peptide length of at least seven amino acids and a
false discovery rate below 0.01 were required on the peptide and protein levels [64].
4.6.4. MS Data Analysis
The raw output files of IsobarQuant (protein.txt files) were processed using the R programming
language (ISBN 3-900051-07-0). As a quality filter, only proteins were allowed that you were quantified
with at least two unique peptides. Human and mouse samples were searched against a combined
human and mouse database and annotated as unique for human or mouse or mixed. Raw signal-sums
(signal_sum columns) were normalized using vsn (variance stabilization normalization) [65]. In order
to try to annotate each observed ratio with a p-value, each ratio distribution was analyzed with the
locfdr function of the locfdr package [66] to extract the average and the standard deviation (using the
maximum likelihood estimation). Then, the ratio distribution was transformed into a z-distribution by
normalizing it by its standard deviation and mean. This z-distribution was analyzed with the fdrtool
function of the fdrtool package [67] in order to extract p-values and false discovery rates (fdr, q-values).
4.7. Tissue Microarray
Tissue microarray core annotations and quantification of positive staining were performed by
QuPath software version v0.2.0-m8 [68] using the TMA map function. Kaplan–Meier curves to calculate
the association between TNC-positive cells and disease progression were calculated using the “survfit”
function and the global Log-Rank test using the Survival R package [69,70]. To estimate the survival,
we used the function “surv_cutpoint”, which employs maximally selected rank statistics (maxstat) to
determine the optimal cut-point for continuous variables [18]. For pairwise comparison, the p-value
was estimated by the Log-Rank test and adjusted with the Benjamini–Hochberg (BH) method. If no
information on patient outcome was available, information at the last follow-up was used for all
parameters. Clinical progression was defined as metastasis or local recurrence. Disease progression
was defined by combining any form of recurrence (PSA and clinical progression). Data representation
and graphical plots were generated using the ggplot2 R package [71]. Data analyses were done using
RStudio version 1.1.463 [72] and R version 3.5.3 [73].
4.8. Immunohistochemistry
FFPE sections (4 µm) were deparaffinized and used for heat-mediated antigen retrieval (citrate
buffer, pH 6, Vector Labs). Sections were blocked for 10 min in 3% H2O2, followed by 30 min,
RT incubation in 1% BSA in PBS–0.1%Tween 20. The following primary antibodies were used (Table 3):
Table 3. Primary antibodies used for Immunohistochemistry
Dilution Antibody Company Catalog No.
1 to 500 Ki67 Gene Tex GTX16667
1 to 100 Tnc R&D MAB2138
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Secondary anti-rabbit antibody Envision HRP (DAKO, Agilent Technologies, Basel, Switzerland)
for 30 min or anti-rat HRP (Thermo Scientific, Basel, Switzerland). Signal detection with AEC substrate
(DAKO, Agilent Technologies, Basel, Switzerland). Sections were counterstained with Hematoxylin
and mounted with Aquatex.
4.9. Immunofluorescence
After deparaffinization, heat-mediated antigen retrieval (citrate buffer, pH 6, Vector Labs) was
performed. Sections were blocked in 1% BSA in PBS–0.1% Tween 20 for 30 min, RT incubation.
The primary antibodies used (Table 4), were incubated overnight in blocking solution at 4 ◦C:
Table 4. Primary antibodies used for Immunofluorescence
Dilution Antibody Company Catalog No.
1 to 500 αSMA Sigma A2547
1 to 500 ITGA2 Abcam ab181548
1 to 500 Collagen type I Southern Biotech 1310-01
1 to 50 Tnc R&D MAB2138
Secondary anti-rabbit/mouse/goat/rat antibodies coupled to Alexa Fluor®-488, 555 or 647
fluorochrome conjugates (Invitrogen, Thermo Scientific, Basel, Switzerland) were incubated for
90 min at 1:250 dilution in PBS. Sections were counterstained with DAPI solution (Thermo Scientific,
Basel, Switzerland, final concentration 1 µg/mL in PBS, 10 min), washed and mounted with prolonged
diamond antifade reagent (Invitrogen, Thermo Scientific, Basel, Switzerland).
5. Conclusions
In this proof-of-concept study, the molecular profile of the stroma in prostate cancer was shown to be
responsive to androgen deprivation even in advanced, androgen-independent bone metastasis prostate
cancer. We identified a stroma-specific gene expression signature that correlates with the Gleason
score and metastatic disease progression of prostate cancer. Given the inevitable drug resistance to
androgen deprivation therapies, stroma biomarker identification associated with resistance acquisition
may complement standard histopathology and genomic evaluations for improved stratification of
patients at high risk.
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